New Design Strategies for Controlling the Rate of Hydrophobic Drug Release from Nanoemulsions in Blood Circulation.
Animals
Antineoplastic Agents
/ administration & dosage
Cinnamates
/ chemistry
Curcumin
/ administration & dosage
Drug Carriers
/ chemistry
Drug Liberation
Emulsions
Female
Hydrophobic and Hydrophilic Interactions
Injections, Intravenous
Mice
Mice, Inbred ICR
Models, Animal
Nanoparticles
/ chemistry
Oils
/ chemistry
Paclitaxel
/ administration & dosage
Pharmaceutic Aids
/ chemistry
Solubility
curcumin
drug delivery
hydrotropy
paclitaxel
plasma retention
premature drug release
π−π stacking
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
05 10 2020
05 10 2020
Historique:
pubmed:
4
9
2020
medline:
3
8
2021
entrez:
4
9
2020
Statut:
ppublish
Résumé
The intravenous administration of drug-loaded nanoparticles (NPs) is needed to achieve passive or active targeting in disease tissues. However, when the loaded drug is a hydrophobic small molecule, the NPs fail to reach adequate plasma drug concentrations mainly because of premature drug release. The pharmacokinetics of such drugs can be controlled by covalent modification, but this approach could compromise the safety or potency of the drug. In this study, we investigated two formulation parameters that could be used to improve the plasma concentrations of unmodified drugs that are loaded in a nanoemulsion (NE), a core-shell type NP. The first parameter is the loading ratio, and the second is the affinity of the drug to the core. Optimized NEs with reduced drug loading and with a high drug-core affinity resulted in a 12.4- and 11.2-fold increase in the plasma retention of curcumin and paclitaxel, respectively. Our strategy for enhancing the drug-core interaction affinity relied on mixing oils and surfactants to achieve cooperativity in noncovalent interactions, such as hydrophobic interactions, hydrogen bonding, and π-π stacking, which was further confirmed by theoretical calculations of interaction affinities. Finally, we report on the development of a cinnamic acid-derived oil-like material as a novel drug vehicle with exceptional solubilizing ability that could be used in intravenous formulations of NEs.
Identifiants
pubmed: 32881529
doi: 10.1021/acs.molpharmaceut.0c00542
doi:
Substances chimiques
Antineoplastic Agents
0
Cinnamates
0
Drug Carriers
0
Emulsions
0
Oils
0
Pharmaceutic Aids
0
cinnamic acid
140-10-3
Curcumin
IT942ZTH98
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM